GTG acquires sports gene test rights from Sydney Uni
08 September, 2003 by Melissa TrudingerMelbourne genetic testing company Genetic Technologies (ASX:GTG) has acquired the exclusive worldwide rights to commercialise a test for a gene underlying athletics and sports performance from the University of Sydney.
EpiTan loss doesn't detract from solid year
08 September, 2003 by Melissa TrudingerMelbourne biotech company EpiTan (ASX:EPT) has posted a loss of AUD$4 million for the 2002-2003 financial year, primarily due to the expenses of running Phase II clinical trials on its lead drug candidate Melanotan.
Prana raises $5m from institutional investors
08 September, 2003 by Melissa TrudingerJoining the list of companies taking advantage of increased investor interest in the biotechnology sector, Prana Biotechnology (ASX:PBT) has raised AUD$5 million in a placement to institutional and sophisticated investors at a price of $0.70 per share.
Xcell collaborators earn $1m NIH grant
05 September, 2003 by Melissa TrudingerCollaborators of Perth devices company Xcell Diagnostics (ASX:XEL) have received a US NIH grant worth more than AUD$1 million (US$702,000) to perform clinical studies on Xcell's Funhaler paediatric asthma spacer device.
Biotron adds dengue virus to discovery roster
04 September, 2003 by Graeme O'NeillCanberra biotechnology company Biotron (ASX: BIT) has added dengue virus to the lengthening list of potentially lethal human viruses that possess ion-channel genes.
UK hints at end to drug price controls
03 September, 2003 by Richard WoodmanThe British government said it might be possible to relax or abolish price and profit controls on branded prescription medicines in the UK.
Agenix appoints new US vet distributor
03 September, 2003 by Iain ScottBrisbane-based Agenix (ASX:AGX) has appointed a new distributor for its animal health diagnostic products in the US.
Anadis therapy aiming to ease travellers' paths
03 September, 2003 by Graeme O'NeillIt's a malady with many colourful names -- Montezuma's revenge, Delhi belly, the Karachi Crouch -- but traveller's diarrhoea, by any other name, has disembowelled many a costly overseas holiday or business trip.
Patent could lead to new royalty revenue: CSL
03 September, 2003 by Iain ScottA new US patent issued to CSL (ASX:CSL) and the University of Queensland over human papillomavirus (HPV) will lead to royalty revenue if drug giant Merck launches a vaccine for the virus in the US.
PanBio tips profit for 2003-04
02 September, 2003 by Melissa TrudingerQueensland-based diagnostics company PanBio (ASX:PBO) has ended the financial year with an anticipated loss, but expects the 2003-2004 year to be profitable, said chairman Ian Sandford today.
S&P raises ResMed ratings
01 September, 2003 by Iain ScottStandard & Poor's ratings services has raised its corporate credit rating on ResMed (ASX:RMD) to 'BB-' from 'B+', and raised its senior subordinated debt rating on the company to 'B' from 'B-'.
Pest solution goes back for mouse-to-mouse resuscitation
01 September, 2003 by Graeme O'NeillPlans to conduct the first contained field trial of a transgenic virus designed to prevent episodic plagues of the house mouse in the Australian wheat belt have been set back while researchers work to improve its transmission under field conditions
Gradipore's loss slightly higher than expected
29 August, 2003 by Iain ScottSydney bioseparations specialist Gradipore (ASX:GDP) has reported an operating loss for 2002-03 of AUD$16.7 million, down from an $18.5 million loss the previous year but slightly higher than the figure forecast by the company in May.
Prima touts human trials hopes for vaccine tech
29 August, 2003 by Melissa TrudingerPrima Biomed subsidiary PanVax is planning to test its DCtag adjuvant technology with an existing marketed vaccine in human clinical trials, aiming to demonstrate enhanced immunogenicity of the re-engineered vaccine compared to existing formulations.
Cancer drug trials lift Progen losses
29 August, 2003 by Graeme O'NeillResearch and development costs -- including the expense of continuing clinical trials of its promising anti-cancer drug PI-88 -- have seen Brisbane drug-development company Progen Industries (ASX:PGL, NASDAQ:PGLAF) post a net operating loss of AUD$7.8 million to June 30.
